Veracyte (VCYT)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Veracyte (VCYT)
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
Key Insights
Critical company metrics and information
Share Price
$43.58Market Cap
$3.38 BillionTotal Outstanding Shares
77.50 Million SharesTotal Employees
815Dividend
No dividendIPO Date
October 30, 2013SIC Description
Services-medical LaboratoriesHomepage
https://www.veracyte.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities, Continuing | $66.12 Million |
Net Cash Flow From Financing Activities, Continuing | $10.06 Million |
Net Cash Flow, Continuing | $71.55 Million |
Net Cash Flow From Investing Activities, Continuing | $-4.63 Million |
Net Cash Flow From Financing Activities | $10.06 Million |
Net Cash Flow From Operating Activities | $66.12 Million |
Net Cash Flow From Investing Activities | $-4.63 Million |
Exchange Gains/Losses | $274,000.00 |
Net Cash Flow | $71.83 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Income/Loss From Continuing Operations After Tax | $-9.27 Million |
Net Income/Loss Attributable To Parent | $-9.27 Million |
Income/Loss From Continuing Operations Before Tax | $-8.17 Million |
Operating Expenses | $439.09 Million |
Benefits Costs and Expenses | $433.50 Million |
Operating Income/Loss | $-23.54 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-9.27 Million |
Net Income/Loss | $-9.27 Million |
Research and Development | $68.68 Million |
Basic Earnings Per Share | $-0.13 |
Revenues | $425.33 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Diluted Average Shares | $77.50 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Basic Average Shares | $76.26 Million |
Diluted Earnings Per Share | $-0.13 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Costs And Expenses | $439.09 Million |
Other Operating Expenses | $370.41 Million |
Income Tax Expense/Benefit | $1.10 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Assets | $356.85 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Equity | $1.18 Billion |
Intangible Assets | $108.87 Million |
Noncurrent Liabilities | $28.67 Million |
Assets | $1.28 Billion |
Inventory | $20.36 Million |
Other Non-current Assets | $809.29 Million |
Equity Attributable To Parent | $1.18 Billion |
Liabilities | $98.98 Million |
Current Liabilities | $70.31 Million |
Noncurrent Assets | $918.17 Million |
Wages | $30.74 Million |
Other Current Liabilities | $29.90 Million |
Accounts Payable | $9.67 Million |
Other Current Assets | $336.49 Million |
Liabilities And Equity | $1.28 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Veracyte (VCYT)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.